Gilead re­calls 2 lots of Vek­lury af­ter in­ves­ti­ga­tion con­firms com­plaint of glass par­tic­u­lates

Two lots of the Covid-19 treat­ment Vek­lury have been re­called by Gilead, the com­pa­ny said last week, af­ter the ap­pear­ance of glass par­tic­u­lates. A cus­tomer com­plaint was con­firmed by Gilead’s in­ves­ti­ga­tion.

Vek­lury, al­so known as remde­sivir 100 mg for in­jec­tion, is used in more than half of hos­pi­tal­ized pa­tients with Covid-19, ac­cord­ing to Gilead. It raked in around $2.8 bil­lion last year, and was the on­ly drug ap­proved by the FDA for this set­ting. But a study out of Eu­rope dubbed Dis­CoV­eRy found that no clin­i­cal ben­e­fit was ob­served in pa­tients who re­ceived the drug over those who got stan­dard of care alone. And while pre­vi­ous stud­ies have linked remde­sivir to a faster time to re­cov­ery, that re­sult was not seen in the Dis­CoV­eRy tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER